NCT00264576

Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults

A Phase 2, Observer-Blinded, Randomized, Multicenter Study in Healthy Adults to Evaluate Safety and Tolerability and to Compare Immunogenicity of a Single Dose of Either an Investigational Trivalent Inactivated Influenza Vaccine Produced in Mammalian Cell Culture or a US-licensed Trivalent Inactivated Influenza Vaccine (Fluvirin®) Produced in Embryonated Hen Eggs

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 613 (actual)
• Sponsor: Novartis Vaccines · Industry
• Sex: All
• Age: 18 Years – 49 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety and immunogenicity of cell culture-derived, inactivated, subunit influenza vaccine in comparison to licensed Fluvirin vaccine administered to healthy adults ages 18 \< 50 years.

Conditions

• Influenza Disease; Flu

Interventions

Type	Name	Description
BIOLOGICAL	Influenza Virus Vaccine

Timeline

• Start date: 2005-10-01
• Primary completion: 2005-12-01
• Completion: 2006-05-01
• First posted: 2005-12-13
• Last updated: 2017-03-24
• Results posted: 2013-01-28

Locations

4 sites across 1 country: United States